28 results
424B5
MAIA
MAIA Biotechnology Inc
14 Feb 24
Prospectus supplement for primary offering
5:18pm
represents one of the key therapeutic targets for cancer treatment. Telomerase is an enzyme that is present in most human cancer cells (over 85 … targets for cancer treatment. Telomerase is an enzyme that is present in most human cancer cells (over 85% in the aggregate), across various tumor
8-K
EX-1.1
MAIA
MAIA Biotechnology Inc
14 Feb 24
Entry into a Material Definitive Agreement
5:15pm
) the actual or potential defendants in, or targets of, any such action include both the indemnified party and the indemnifying party and the indemnified party
424B5
MAIA
MAIA Biotechnology Inc
17 Nov 23
Prospectus supplement for primary offering
9:06am
, and thus represents one of the key therapeutic targets for cancer treatment. Telomerase is an enzyme that is present in most human cancer cells … , financial and share distribution targets, including maintaining a minimum amount of stockholders’ equity and a minimum number of public stockholders
424B5
7ymt5m36y3e4
1 Sep 23
Prospectus supplement for primary offering
4:30pm
S-3
qcs3ce1z5m0k062hq 9v
14 Aug 23
Shelf registration
6:05pm
DRS
j25uz2jx92v
1 Jun 23
Draft registration statement
12:00am
424B4
kukmhwk62q57 3377wyc
25 Apr 23
Prospectus supplement with pricing info
7:45pm
DRS
5gqbnd
23 Dec 22
Draft registration statement
12:00am
8-K
EX-99.1
cyj8 jtuvjgz
9 Nov 22
MAIA Biotechnology Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:30pm
8-K
EX-99.1
x9lwwwrdir3
7 Sep 22
Regulation FD Disclosure
6:55am
424B4
yzhqeo
29 Jul 22
Prospectus supplement with pricing info
8:31am
FWP
g40b58xsagaolruj1
13 Jul 22
Free writing prospectus
9:58pm